<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328130</url>
  </required_header>
  <id_info>
    <org_study_id>HORA-PDE6B-001</org_study_id>
    <secondary_id>2016-001429-16</secondary_id>
    <nct_id>NCT03328130</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene</brief_title>
  <official_title>Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horama S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horama S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a Phase I/II, monocentric, open-label, dose-ranging safety and efficacy gene
      therapy intervention by subretinal administration of AAV2/5-hPDE6B. At least twelve patients
      18 years of age or older, within three consecutive cohorts of patients, will be recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis pigmentosa (RP) is a disease where part of the eye (the retina) is degenerating
      over time. Patients initially present with night blindness, and later in life experience loss
      of central vision which leads to blindness. RP is a highly variable disorder with some
      patients developing symptomatic visual loss in childhood whereas others remain asymptomatic
      until mid-adulthood. There are no treatments available.

      This study focuses on the form of RP caused by mutations (modifications) in the genetic
      information necessary to make the protein called rod cGMP phosphodiesterase 6 β subunit (or
      PDE6β). Clinical diagnosis is made by function tests of the eye and confirmed using a
      specific method called molecular testing to verify that the PDE6B gene is not correct.

      This study uses a gene therapy vector inspired from an adeno-associated virus (AAV) called
      AAV2/5-hPDE6B. This vector intends to supply to the target cells the PDE6B therapeutic gene
      that is not functioning properly in the cell. The AAV parts of the gene therapy vector work
      as a vehicle to deliver the normal human PDE6B gene into the cells of the retina.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Three successive cohorts separated by DSMC assessments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of ocular and non-ocular adverse events</measure>
    <time_frame>1 year + 2 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in visual function</measure>
    <time_frame>1 year + 2 years follow-up</time_frame>
    <description>Improvement in visual function as assessed by mobility test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in visual fields</measure>
    <time_frame>1 year + 2 years follow-up</time_frame>
    <description>Improvement in visual fields as assessed by visual fields measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in visual function</measure>
    <time_frame>1 year + 2 years follow-up</time_frame>
    <description>Improvement in visual function as assessed by reading speed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>1 year + 2 years follow-up</time_frame>
    <description>Quality of life will be measured by Quality of Life questionnaire National Eye Institute Visual Function Questionnaire (NEI VFQ-25)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Confirmatory Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV2/5-hPDE6B</intervention_name>
    <description>Subretinal administration in one eye</description>
    <arm_group_label>Cohort 1 - Low Dose</arm_group_label>
    <arm_group_label>Cohort 2 - High Dose</arm_group_label>
    <arm_group_label>Cohort 3 - Confirmatory Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Clinical and molecular diagnosis of retinitis pigmentosa caused by defect in PDE6B
             gene without other syndromic manifestations

          -  Aged 18 years or older

          -  Ability to give informed consent

        Key Exclusion Criteria:

          -  Previous ocular surgery or thermal laser within 6 months before the surgery

          -  Lens opacities or obscured ocular media upon recruitment such reliable evaluation or
             grading of the posterior segment cannot be performed

          -  Known serious allergies to the fluorescein dye used in angiography, to the mydriatic,
             steroidal and non-steroidal eye drops

          -  Participation in another clinical trial with an investigational agent

          -  Enrolled or being enrolled in another gene therapy clinical trial

          -  Active, extraocular infection requiring the prolonged or chronic use of antimicrobial
             agents

          -  Chronic medical conditions, cancer

          -  Abnormal laboratory values

          -  On immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Yves Deslandes</last_name>
    <phone>33 (0)1 81 69 87 72</phone>
    <email>jy.deslandes@horama.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Séverine Marconi</last_name>
    <phone>33 (0)6 22 73 26 34</phone>
    <email>s.marconi@horama.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Ophtalmologique, CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Lebranchu</last_name>
      <email>pierre.lebranchu@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Petit L, Lhériteau E, Weber M, Le Meur G, Deschamps JY, Provost N, Mendes-Madeira A, Libeau L, Guihal C, Colle MA, Moullier P, Rolling F. Restoration of vision in the pde6β-deficient dog, a large animal model of rod-cone dystrophy. Mol Ther. 2012 Nov;20(11):2019-30. doi: 10.1038/mt.2012.134. Epub 2012 Jul 24.</citation>
    <PMID>22828504</PMID>
  </results_reference>
  <results_reference>
    <citation>Pichard V, Provost N, Mendes-Madeira A, Libeau L, Hulin P, Tshilenge KT, Biget M, Ameline B, Deschamps JY, Weber M, Le Meur G, Colle MA, Moullier P, Rolling F. AAV-mediated Gene Therapy Halts Retinal Degeneration in PDE6β-deficient Dogs. Mol Ther. 2016 May;24(5):867-76. doi: 10.1038/mt.2016.37. Epub 2016 Feb 9.</citation>
    <PMID>26857842</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adeno-associated virus</keyword>
  <keyword>AAV</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>PDE6B</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Gene Transfer</keyword>
  <keyword>Retinal Dystrophy</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Vision Disorders</keyword>
  <keyword>Eye Diseases, Hereditary</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Retinal Degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

